NovoCare Pharmacy (Wegovy) vs TrimRx (2026): prices, structure, verdict

On tirzepatide, only TrimRx↗ has a rankable figure: $349 a month all-in; NovoCare Pharmacy (Wegovy)↗ does not offer tirzepatide.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, TrimRx is cheaper: $299 versus $349 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

NovoCare Pharmacy (Wegovy): the record, condensed

NovoCare Pharmacy (Wegovy)’s semaglutide program bills $349 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at NovoCare Pharmacy (Wegovy) is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes NovoCare Pharmacy (Wegovy) unusually easy to compare and unusually easy to leave.

To place the number: #0 of 20 verified programs, with the floor $216/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $4,188 monthly-billed.

Operationally at NovoCare Pharmacy (Wegovy): shipping included (or retail via savings card); commitment none; cancellation no subscription; pharmacy named (Novo Nordisk direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NovoCare Pharmacy (Wegovy) page · visit NovoCare Pharmacy (Wegovy) ↗

TrimRx: the record, condensed

TrimRx’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes TrimRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #11 of 17 in the verified tirzepatide index — $134/month above the floor (NexLife↗, $215) — and sits $100 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,188.

TrimRx’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at TrimRx is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #17 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at TrimRx: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the TrimRx page · visit TrimRx ↗

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: TrimRx at $299, NovoCare Pharmacy (Wegovy) at $349 — a $50 monthly spread that compounds to $600 over a maintenance year and $1,200 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $50 gap is exactly what it appears to be.

Translate the $50/month spread into medication: $600 a year equals roughly 2.0 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: NovoCare Pharmacy (Wegovy) $349/mo month-to-month versus TrimRx $299/mo month-to-month. Same winner on both bases — TrimRx leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: NovoCare Pharmacy (Wegovy) $1,047 monthly; TrimRx $897 monthly — best path favors TrimRx by $150. 6 months: NovoCare Pharmacy (Wegovy) $2,094 monthly; TrimRx $1,794 monthly — best path favors TrimRx by $300. 12 months: NovoCare Pharmacy (Wegovy) $4,188 monthly; TrimRx $3,588 monthly — best path favors TrimRx by $600. 24 months: NovoCare Pharmacy (Wegovy) $8,376 monthly; TrimRx $7,176 monthly — best path favors TrimRx by $1,200.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: NovoCare Pharmacy (Wegovy) publishes “50 states”; TrimRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NovoCare Pharmacy (Wegovy) names its network (Novo Nordisk direct / retail partners); TrimRx does not, which shifts the burden of verification onto your intake questions.

Exit terms: NovoCare Pharmacy (Wegovy) — none; no subscription. TrimRx — none month-to-month; check terms before prepaying.

Evidence: NovoCare Pharmacy (Wegovy) source-verified (captured 2026-08-10); TrimRx source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between NovoCare Pharmacy (Wegovy) and TrimRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (NovoCare Pharmacy (Wegovy): no subscription; TrimRx: check terms before prepaying) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings